Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Zou, Xue-lin; Wang, Chun; Liu, Ke; Nie, Wen; Ding, Zhenyu

doi:10.3892/mco.2015.517

Cited by 13 publications

(12 citation statements)

References 31 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, low serum OPN levels were significantly associated with a favorable prognosis in advanced NSCLC (26). Two recent meta-analyses confirmed that OPN seems to be a good prognostic biomarker of the overall survival in NSCLC patients (27,28). These findings are in accordance with the satisfactory prognostic performance of OPN in 1-year survival observed in our study.…”

Section: Serumsupporting

confidence: 91%

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Serumsupporting

confidence: 91%

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We found several previously published meta-analyses also explored the prognostic significance of OPN in different cancers including breast cancer [ 31 ], colorectal cancer [ 32 ], non-small-cell lung cancer [ 33 ] and glioma [ 34 ]. Xu et al showed that OPN expression was a predictor for poor overall survival and disease-free survival in breast cancer patients [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis

Gao

et al. 2016

Oncotarget

View full text Add to dashboard Cite

BackgroundAccumulated studies have exploited the association between osteopontin (OPN) expression and survival of patients with gastric cancer (GC), however, the results were controversial. Thus, we performed a meta-analysis, aiming to investigate the prognostic role of OPN for GC patients and to explore the association between OPN and clinicalpathological features of GC.ResultsA total of ten studies involving 1775 patients were included in final meta-analysis. Of the included studies, nine were conducted on Asian patients and one was performed on Caucasian patients. Regarding OPN detection, immunohistochemistry (IHC) was used on tissue specimens in eight studies and enzyme linked immunosorbent assay (ELISA) was used on plasma specimens in two studies. The pooled data showed that high OPN expression was correlated with poor OS (HR = 1.59, 95% CI: 1.15–2.22, p = 0.006). Subgroup analyses demonstrated that OPN had enhanced prognostic value for Asian patients (HR = 1.64, 95% CI = 1.11–2.41, p = 0.012) and for patients receiving surgical resection (HR = 1.6, 95% CI = 1.04–2.48, p = 0.034). In addition, the results also showed that elevated OPN expression was associated with lymph node metastasis, TNM stage, depth of invasion, tumor size and distant metastasis in GC.MethodsRelevant studies were retrieved through PubMed, Embase and Web of Science. Combined hazard ratio (HR) and 95% confidence interval (CI) were calculated to assess the association between OPN and overall survival (OS). Subgroup analyses and publication bias were also conducted.ConclusionsOPN overexpression was correlated with poor OS and clinical features reflecting high aggressiveness in patients with GC. OPN was a promising prognostic biomarker for GC.

show abstract

“…OPN is up-regulated in NSCLC and even more in cells with strong potential and capacity of metastasis and invasion [18,19], which can be attenuated by its deletion [20]. Up-regulation of OPN is proposed to be associated with stages, severities, lymph node metastasis, poor prognosis, and high recurrence [21][22][23]. However, it is still unclear whether OPN is responsible for acquired resistance to EGFR-TKIs.…”

mentioning

confidence: 99%

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Zhang

et al. 2020

J Hematol Oncol

View full text Add to dashboard Cite

Background Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although most of the mechanisms of acquired EGFR-TKI resistance have been revealed, the mechanism of ~ 15% of cases has not yet been elucidated. Methods Cell viability was analysed using the Cell Counting Kit-8 (CCK-8) assay. Proteome profiler array analysis was performed to find proteins contributing to acquired EGFR-TKI resistance. Secreted OPN was detected by ELISA. Immunohistochemical analysis was conducted to detect expression of integrin αV in NSCLC tissue. The effect of VS-6063 on apoptosis and proliferation of PC9 gefitinib-resistant cells was detected by fluorescence-activated cell sorting (FACS) and clonogenic assays. A mouse xenograft model was used to assess the effect of VS-6063 on the sensitivity of PC9 gefitinib-resistant cells to gefitinib. Results OPN was overexpressed in acquired EGFR-TKI-resistant NSCLCs. Secreted OPN contributed to acquired EGFR-TKI resistance by activating the integrin αVβ3/FAK pathway. Inhibition of FAK signalling increased sensitivity to EGFR-TKIs in PC9 gefitinib-resistant cells both in vitro and in vivo. Conclusions OPN contributes to acquired EGFR-TKI resistance by up-regulating expression of integrin αVβ3, which activates the downstream FAK/AKT and ERK signalling pathways to promote cell proliferation in NSCLC.

show abstract

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Cited by 13 publications

References 31 publications

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Contact Info

Product

Resources

About